← All trials
NCT06697899
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 20, 2024
- Primary completion
- Jan 20, 2025
- Completion date
- Feb 20, 2025
- First posted
- Nov 20, 2024
- Last posted
- Nov 20, 2024
- Enrollment
- 72
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Government of ChinaLead sponsor
- Nanjing Medical UniversityOfficial
- Nanjing UniversityCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.